Aegera Therapeutics Collaboration with Human Genome Sciences Leads to the Initiation of a Phase 1 Clinical Trial with Lead IAP Inhibitor HGS1029 and Receipt of First Milestone Payment
... diabetic neuropathy and is in Phase I clinical studies. Website: CONTACT: Donald Olds, MSc, MBA, Chief Operating Officer & CFO, AegeraTherapeutics Inc., (514) 288-5532 (x)295, Terms and conditions of ...
More...
... diabetic neuropathy and is in Phase I clinical studies. Website: CONTACT: Donald Olds, MSc, MBA, Chief Operating Officer & CFO, AegeraTherapeutics Inc., (514) 288-5532 (x)295, Terms and conditions of ...
More...